| [1] | Thiel J., Schlegel J.A., Liang C., et al. (2026). The FAP × CD3 bispecific antibody OMTX305 induces T cell-mediated antitumor effects in patient-derived ex vivo models of solid tumors. Sci. Adv. 12:eaee2124. DOI:10.1126/sciadv.aee2124 |
| [2] | Klein C., Brinkmann U., Reichert J.M., et al. (2024). The present and future of bispecific antibodies for cancer therapy. Nat. Rev. Drug Discov. 23:301−319. DOI:10.1038/s41573-024-00896-6 |
| [3] | Grout J.A., Sirven P., Leader A.M., et al. (2022). Spatial positioning and matrix programs of cancer-associated fibroblasts promote T-cell exclusion in human lung tumors. Cancer Discov. 12:2606−2625. DOI:10.1158/2159-8290.CD-21-1714 |
| [4] | Feng Z., Liu S., Wu Y., et al. (2026). 68Gallium-labelled FAP-inhibitors outperforms 18F-fluorodeoxyglucose PET/CT for recurrent ovarian cancer in the poly adenosine diphosphate-ribose polymerase inhibitor era. Chin. Med. J. Published online March 11:2026. DOI:10.1097/CM9.0000000000003976 |
| [5] | Melero I., Tanos T., Bustamante M., et al. (2023). A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors. Sci. Transl. Med. 15:eabp9229. DOI:10.1126/scitranslmed.abp9229 |
| Wu Y., Liu S., Feng Z., et al. (2026). From stromal barrier to immune anchor: A translational view of FAP×CD3 engagement with OMTX305. The Innovation Oncology 1:100035. https://doi.org/10.59717/j.xinn-oncol.2026.100035 |
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
OMTX305 mechanism and a proposed biomarker-guided framework for FAP×CD3 therapy